BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, Solomon M, McCrindle BW, Grant D. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14:968-975. [PMID: 21040278 DOI: 10.1111/j.1399-3046.2010.01409.x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 109] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Cukor D, Ver Halen N, Pencille M, Tedla F, Salifu M. A Pilot Randomized Controlled Trial to Promote Immunosuppressant Adherence in Adult Kidney Transplant Recipients. Nephron 2017;135:6-14. [PMID: 28049201 DOI: 10.1159/000448627] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
2 de Oliveira JTP, Kieling CO, da Silva AB, Stefani J, Witkowski MC, Smidt CR, Mariano da Rocha CR, Hirakata VN, Grossini MDG, Zanotelli ML, Gonçalves Vieira SM. Variability index of tacrolimus serum levels in pediatric liver transplant recipients younger than 12 years: Non-adherence or risk of non-adherence? Pediatr Transplantation 2017;21:e13058. [DOI: 10.1111/petr.13058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
3 Malik S, Hamer R, Shabir S, Youssouf S, Morsy M, Rashid R, Waqar S, Ghouri N. Effects of fasting on solid organ transplant recipients during Ramadan - a practical guide for healthcare professionals. Clin Med (Lond) 2021;21:e492-8. [PMID: 34507933 DOI: 10.7861/clinmed.2021-0250] [Reference Citation Analysis]
4 Varnell CD Jr, Rich KL, Zhang B, Carle AC, Pai ALH, Modi AC, Hooper DK. Predicting acute rejection in children, adolescents, and young adults with a kidney transplant by assessing barriers to taking medication. Pediatr Nephrol 2021;36:2453-61. [PMID: 33501558 DOI: 10.1007/s00467-021-04946-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sirota M, Heyrend C, Ou Z, Masotti S, Griffiths E, Molina K. Impact of tacrolimus variability on pediatric heart transplant outcomes. Pediatr Transplant 2021;:e14043. [PMID: 34390091 DOI: 10.1111/petr.14043] [Reference Citation Analysis]
6 Riva N, Dip M, Halac E, Cáceres Guido P, Woillard JB, Licciardone N, Chan D, Buendía J, Borgnia D, Bosaleh A, de Davila MT, Imventarza O, Schaiquevich P. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. Ther Drug Monit 2018;40:401-10. [PMID: 29621122 DOI: 10.1097/FTD.0000000000000517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
7 Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 2018;32:e13424. [PMID: 30318646 DOI: 10.1111/ctr.13424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
8 Stevens JP, Hall L, Gupta NA. TRANSITION of Pediatric Liver Transplant Patients to Adult Care: a Review. Curr Gastroenterol Rep 2021;23:3. [PMID: 33523312 DOI: 10.1007/s11894-020-00802-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Annunziato RA, Parbhakar M, Kapoor K, Matloff R, Casey N, Benchimol C, Hotchkiss H, Nair V, Saland J. Can Transition to Adult Care for Transplant Recipients Be Improved by Intensified Services While Patients are Still in Pediatrics? Prog Transpl 2015;25:236-42. [DOI: 10.7182/pit2015599] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Koop DR, Bleyle LA, Munar M, Cherala G, Al-Uzri A. Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013;926:54-61. [PMID: 23548676 DOI: 10.1016/j.jchromb.2013.02.035] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
11 Jia JJ, Lin BY, He JJ, Geng L, Kadel D, Wang L, Yu DD, Shen T, Yang Z, Ye YF, Zhou L, Zheng SS. ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation. World J Gastroenterol 2014; 20(32): 11363-11369 [PMID: 25170223 DOI: 10.3748/wjg.v20.i32.11363] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
12 Notaro E, Brown L, Albers E, Law S, Kemna M. Dose conversion factor between cyclosporine and tacrolimus in pediatric heart transplant recipients. J Heart Lung Transplant 2014;33:766-8. [PMID: 24854566 DOI: 10.1016/j.healun.2014.04.004] [Reference Citation Analysis]
13 Duncan-Park S, Danziger-Isakov L, Armstrong B, Williams N, Odim J, Shemesh E, Sweet S, Annunziato R. Posttraumatic stress and medication adherence in pediatric transplant recipients. Am J Transplant 2021. [PMID: 34837457 DOI: 10.1111/ajt.16896] [Reference Citation Analysis]
14 Kim SY, Jeong SJ, Lee JG, Park MS, Paik HC, Na S, Kim J. Critical Care after Lung Transplantation. Acute Crit Care 2018;33:206-15. [PMID: 31723887 DOI: 10.4266/acc.2018.00360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Mitchell T, Gooding H, Mews C, Adams L, MacQuillan G, Garas G, Ravikumara M, Lopez A, Collins M, Jeffrey G. Transition to adult care for pediatric liver transplant recipients: the Western Australian experience. Pediatr Transplant 2017;21. [PMID: 27762479 DOI: 10.1111/petr.12820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Song T, Yin S, Jiang Y, Huang Z, Liu J, Wang Z, Li L, Zeng J, Fan Y, Wang X, Li X, Lin T. Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. Front Immunol 2019;10:2912. [PMID: 31921171 DOI: 10.3389/fimmu.2019.02912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Christina S, Annunziato RA, Schiano TD, Anand R, Vaidya S, Chuang K, Zack Y, Florman S, Shneider BL, Shemesh E. Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. Liver Transpl. 2014;20:1168-1177. [PMID: 24931127 DOI: 10.1002/lt.23930] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]
18 Cao Z, Li C, He J, Sui X, Wu P, Pan D, Qing L, Tang J. FK506-loaded PLGA nanoparticles improve long-term survival of a vascularized composite allograft in a murine model. Ann Transl Med 2021;9:1515. [PMID: 34790721 DOI: 10.21037/atm-21-2425] [Reference Citation Analysis]
19 Eid L, Tuchman S, Moudgil A. Late acute rejection: incidence, risk factors, and effect on graft survival and function. Pediatr Transplant 2014;18:155-62. [PMID: 24372967 DOI: 10.1111/petr.12203] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
20 Bestard O, Sarwal MM. Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression. Pediatr Nephrol 2015;30:397-403. [DOI: 10.1007/s00467-014-3020-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
21 Prytula AA, Bouts AH, Mathot RAA, van Gelder T, Croes LK, Hop W, Cransberg K. Intra-patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients: Intra-patient tacrolimus levels variability. Pediatric Transplantation 2012;16:613-8. [DOI: 10.1111/j.1399-3046.2012.01727.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
22 Filler G, Bravo M. Appreciating the need for greater understanding of the pharmacokinetics of drugs in children and adolescents. Pediatr Transplant 2018;22:e13312. [PMID: 30499623 DOI: 10.1111/petr.13312] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Ensor CR, Iasella CJ, Harrigan KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant 2018;18:1527-33. [PMID: 29513387 DOI: 10.1111/ajt.14723] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
24 van der Veer MAA, Nangrahary N, Hesselink DA, Erler NS, Metselaar HJ, van Gelder T, Darwish Murad S. High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. Transplantation 2019;103:2329-37. [PMID: 30801539 DOI: 10.1097/TP.0000000000002680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
25 Chandran MM, Blanchette E, Goebel J, Bock M. Impact of once-daily ER-Tac on trough concentration variability in a stable AYA renal transplant recipient cohort. Pediatr Transplant 2021;25:e14036. [PMID: 34003550 DOI: 10.1111/petr.14036] [Reference Citation Analysis]
26 Suhling H, Rademacher J, Zinowsky I, Fuge J, Greer M, Warnecke G, Smits JM, Bertram A, Haverich A, Welte T, Gottlieb J. Conventional vs. tablet computer-based patient education following lung transplantation--a randomized controlled trial. PLoS One 2014;9:e90828. [PMID: 24608864 DOI: 10.1371/journal.pone.0090828] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
27 Krämer B, Albano L, Banas B, Charpentier B, Bäckman L, Tedesco-silva H, Lehner F, Mondragón-ramírez G, Glyda M, Cassuto-viguier E, Viklický O, Mourad G, Rigotti P, Schleibner S, Kamar N. Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. Transplantation Proceedings 2017;49:2040-9. [DOI: 10.1016/j.transproceed.2017.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
28 Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective. Pharmacotherapy 2021;41:103-18. [PMID: 33131078 DOI: 10.1002/phar.2480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Angelico R, Sensi B, Manzia TM, Tisone G, Grassi G, Signorello A, Milana M, Lenci I, Baiocchi L. Chronic rejection after liver transplantation: Opening the Pandora’s box. World J Gastroenterol 2021; 27(45): 7771-7783 [PMID: 34963740 DOI: 10.3748/wjg.v27.i45.7771] [Reference Citation Analysis]
30 Staatz CE, Tett SE. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet 2015;54:993-1025. [DOI: 10.1007/s40262-015-0282-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
31 Ho B, Bhagat H, Schwartz JJ, Atiemo K, Daud A, Kang R, Montag SE, Zhao L, Lee E, Skaro AI, Ladner DP. Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization. Adv Ther 2019;36:1465-79. [PMID: 30941724 DOI: 10.1007/s12325-019-00904-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015;29:78-84. [PMID: 25687818 DOI: 10.1016/j.trre.2015.01.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 14.9] [Reference Citation Analysis]
33 Bessa AB, Felipe CR, Hannun P, Sayuri P, Felix MJ, Ruppel P, Ferreira AN, Cristelli MP, Viana L, Mansur JF, Basso G, Aguiar WF, Tedesco-silva H, Medina-pestana J. Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intra-Individual Variability of Tacrolimus Concentrations Early After Kidney Transplant. Therapeutic Drug Monitoring 2016;38:447-55. [DOI: 10.1097/ftd.0000000000000299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
34 Ferrarese A, Germani G, Lazzaro S, Cananzi M, Russo FP, Senzolo M, Gambato M, Zanetto A, Cillo U, Gringeri E, Perilongo G, Burra P. Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. Liver Int 2018;38:1316-21. [PMID: 29205755 DOI: 10.1111/liv.13655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
35 Kerr SM, Jorgensen NW, Hong BJ, Friedland-Little JM, Albers EL, Newland DM, Law YM, Kemna MS. Assessment of rejection risk following subtherapeutic calcineurin inhibitor levels after pediatric heart transplantation. Pediatr Transplant 2020;24:e13616. [PMID: 31820529 DOI: 10.1111/petr.13616] [Reference Citation Analysis]
36 Gallagher HM, Sarwar G, Tse T, Sladden TM, Hii E, Yerkovich ST, Hopkins PM, Chambers DC. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. The Journal of Heart and Lung Transplantation 2015;34:1442-8. [DOI: 10.1016/j.healun.2015.05.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
37 Han N, Ha S, Yun H, Kim MG, Min S, Ha J, Lee JI, Oh JM, Kim I. Population Pharmacokinetic-Pharmacogenetic Model of Tacrolimus in the Early Period after Kidney Transplantation. Basic Clin Pharmacol Toxicol 2014;114:400-6. [DOI: 10.1111/bcpt.12176] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
38 Riva N, Guido PC, Ibañez J, Licciardone N, Rousseau M, Mato G, Monteverde M, Schaiquevich P. Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin. Int J Clin Pharm 2014;36:779-86. [DOI: 10.1007/s11096-014-9959-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
39 Mcdiarmid SV. Adolescence: Challenges and responses: Adolescence: Challenges and Responses. Liver Transpl 2013;19:S35-9. [DOI: 10.1002/lt.23740] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
40 Wadhwani SI, Bucuvalas JC, Brokamp C, Anand R, Gupta A, Taylor S, Shemesh E, Beck AF. Association Between Neighborhood-level Socioeconomic Deprivation and the Medication Level Variability Index for Children Following Liver Transplantation. Transplantation 2020;104:2346-53. [PMID: 32032293 DOI: 10.1097/TP.0000000000003157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
41 Maciel NB, Schwambach KH, Blatt CR. LIVER TRANSPLANTATION: TACROLIMUS BLOOD LEVELS VARIATION AND SURVIVAL, REJECTION AND DEATH OUTCOMES. Arq Gastroenterol 2021;58:370-6. [PMID: 34705973 DOI: 10.1590/S0004-2803.202100000-62] [Reference Citation Analysis]
42 Wildman MJ, Hoo ZH. Moving cystic fibrosis care from rescue to prevention by embedding adherence measurement in routine care. Paediatr Respir Rev 2014;15 Suppl 1:16-8. [PMID: 24835307 DOI: 10.1016/j.prrv.2014.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
43 Ryckewaert A, Allain-launay E, Moreau A, Blancho G, Cesbron A, Blin N, Roussey G. Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient. Pediatr Transplantation 2013;17:E131-6. [DOI: 10.1111/petr.12113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
44 Arias M, Serón D, Herrero I, Rush DN, Wiebe C, Nickerson PW, Ussetti P, Rodrigo E, de Cos M. Subclinical Antibody-Mediated Rejection. Transplantation 2017;101:S1-S18. [DOI: 10.1097/tp.0000000000001735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Dipchand AI. Current state of pediatric cardiac transplantation. Ann Cardiothorac Surg 2018;7:31-55. [PMID: 29492382 DOI: 10.21037/acs.2018.01.07] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
46 Drick N, Seeliger B, Fuge J, Tudorache I, Greer M, Welte T, Haverich A, Gottlieb J. Self-reported non-adherence to immunosuppressive medication in adult lung transplant recipients-A single-center cross-sectional study. Clin Transplant 2018;32:e13214. [DOI: 10.1111/ctr.13214] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
47 Papaz T, Allen U, Blydt-Hansen T, Birk PE, Min S, Hamiwka L, Phan V, Schechter T, Wall DA, Urschel S, Foster BJ, Mital S. Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy (POSITIVE Study): The Collaboration and Design of a National Transplant Precision Medicine Program. Transplant Direct 2018;4:e410. [PMID: 30584591 DOI: 10.1097/TXD.0000000000000842] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
48 Solomon S, Colovai A, Del Rio M, Hayde N. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients. Pediatr Nephrol 2020;35:261-70. [DOI: 10.1007/s00467-019-04377-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. Am J Transplant. 2016;16:2954-2963. [PMID: 27013142 DOI: 10.1111/ajt.13803] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
50 Sablik KA, Clahsen-van Groningen MC, Hesselink DA, van Gelder T, Betjes MGH. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One 2018;13:e0196552. [PMID: 29746495 DOI: 10.1371/journal.pone.0196552] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
51 Rozen-Zvi B, Schneider S, Lichtenberg S, Green H, Cohen O, Gafter U, Chagnac A, Mor E, Rahamimov R. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation. Nephrol Dial Transplant 2017;32:393-9. [PMID: 28025383 DOI: 10.1093/ndt/gfw394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
52 Ivulich S, Westall G, Dooley M, Snell G. The Evolution of Lung Transplant Immunosuppression. Drugs 2018;78:965-82. [DOI: 10.1007/s40265-018-0930-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
53 Kim J, Wilson S, Undre NA, Shi F, Kristy RM, Schwartz JJ. A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation. Drugs R D 2019;19:201-12. [PMID: 31073875 DOI: 10.1007/s40268-019-0271-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
54 Dorr CR, Oetting WS, Jacobson PA, Israni AK. Genetics of acute rejection after kidney transplantation. Transpl Int 2018;31:263-77. [PMID: 29030886 DOI: 10.1111/tri.13084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
55 Kreuzer M, Prüfe J, Oldhafer M, Bethe D, Dierks ML, Müther S, Thumfart J, Hoppe B, Büscher A, Rascher W, Hansen M, Pohl M, Kemper MJ, Drube J, Rieger S, John U, Taylan C, Dittrich K, Hollenbach S, Klaus G, Fehrenbach H, Kranz B, Montoya C, Lange-Sperandio B, Ruckenbrodt B, Billing H, Staude H, Heindl-Rusai K, Brunkhorst R, Pape L. Transitional Care and Adherence of Adolescents and Young Adults After Kidney Transplantation in Germany and Austria: A Binational Observatory Census Within the TRANSNephro Trial. Medicine (Baltimore) 2015;94:e2196. [PMID: 26632907 DOI: 10.1097/MD.0000000000002196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
56 Leven EA, Annunziato R, Helcer J, Lieber SR, Knight CS, Wlodarkiewicz C, Soriano RP, Florman SS, Schiano TD, Shemesh E. Medication adherence and rejection rates in older vs younger adult liver transplant recipients. Clin Transplant 2017;31. [PMID: 28370346 DOI: 10.1111/ctr.12981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
57 Rodrigo E, Segundo DS, Fernández-Fresnedo G, López-Hoyos M, Benito A, Ruiz JC, de Cos MA, Arias M. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. Transplantation 2016;100:2479-85. [PMID: 26703349 DOI: 10.1097/TP.0000000000001040] [Cited by in Crossref: 113] [Cited by in F6Publishing: 46] [Article Influence: 22.6] [Reference Citation Analysis]
58 Scheel J, Reber S, Stoessel L, Waldmann E, Jank S, Eckardt KU, Grundmann F, Vitinius F, de Zwaan M, Bertram A, Erim Y. Patient-reported non-adherence and immunosuppressant trough levels are associated with rejection after renal transplantation. BMC Nephrol 2017;18:107. [PMID: 28356080 DOI: 10.1186/s12882-017-0517-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
59 Knight SR. Intrapatient variability in tacrolimus exposure - a useful tool for clinical practice? Transpl Int 2016;29:1155-7. [DOI: 10.1111/tri.12806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
60 Fernandez HE, Amaral S, Shaw PA, Doyle AM, Bloom RD, Palmer JA, Baluarte HJ, Furth SL. The effect of transfer to adult transplant care on kidney function and immunosuppressant drug level variability in pediatric kidney transplant recipients. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13527] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Herblum J, Dacouris N, Huang M, Zaltzman J, Prasad GVR, Nash M, Chen L. Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence. Can J Kidney Health Dis 2021;8:20543581211021742. [PMID: 34188946 DOI: 10.1177/20543581211021742] [Reference Citation Analysis]
62 Duncan-Park S, Dunphy C, Becker J, D'Urso C, Annunziato R, Blatter J, Conrad C, Goldfarb SB, Hayes D Jr, Melicoff E, Schecter M, Visner G, Armstrong B, Chin H, Kesler K, Williams NM, Odim JN, Sweet SC, Danziger-Isakov L, Shemesh E. Remote intervention engagement and outcomes in the Clinical Trials in Organ Transplantation in Children consortium multisite trial. Am J Transplant 2021;21:3112-22. [PMID: 33752251 DOI: 10.1111/ajt.16567] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Foster BJ, Pai A, Zhao H, Furth S; TAKE-IT Study Group. The TAKE-IT study: aims, design, and methods. BMC Nephrol 2014;15:139. [PMID: 25176317 DOI: 10.1186/1471-2369-15-139] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
64 Snell GI, Westall GP, Paraskeva MA. Immunosuppression and allograft rejection following lung transplantation: evidence to date. Drugs 2013;73:1793-813. [PMID: 24142409 DOI: 10.1007/s40265-013-0136-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
65 Verma M, Awdishu L, Lane J, Park K, Bahur B, Lwin W, McGee H, Steiner R, Finn P, Perkins D. Impact of single immunosuppressive drug withdrawal on lymphocyte immunoreactivity. J Surg Res 2014;188:309-15. [PMID: 24485875 DOI: 10.1016/j.jss.2013.11.1085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Hoo ZH, Campbell MJ, Curley R, Wildman MJ. An empirical method to cluster objective nebulizer adherence data among adults with cystic fibrosis. Patient Prefer Adherence 2017;11:631-42. [PMID: 28392678 DOI: 10.2147/PPA.S131497] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Gustavsen MT, Midtvedt K, Lønning K, Jacobsen T, Reisaeter AV, De Geest S, Andersen MH, Hartmann A, Åsberg A. Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation - a single-centre open prospective trial. Transpl Int 2019;32:614-25. [DOI: 10.1111/tri.13412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
68 Jouve T, Noble J, Rostaing L, Malvezzi P. An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization. Expert Opinion on Drug Safety 2019;18:285-94. [DOI: 10.1080/14740338.2019.1599858] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
69 Whalen HR, Glen JA, Harkins V, Stevens KK, Jardine AG, Geddes CC, Clancy MJ. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. Transplantation 2017;101:430-6. [PMID: 26950724 DOI: 10.1097/TP.0000000000001129] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 8.8] [Reference Citation Analysis]
70 Shemesh E, Bucuvalas JC, Anand R, Mazariegos GV, Alonso EM, Venick RS, Reyes-Mugica M, Annunziato RA, Shneider BL. The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. Am J Transplant. 2017;17:2668-2678. [PMID: 28321975 DOI: 10.1111/ajt.14276] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
71 Bethany JF, Ahna LP. Adherence in Adolescent and Young Adult Kidney Transplant Recipients. TOUNJ 2014;7:133-43. [DOI: 10.2174/1874303x014070100133] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Gold A, Tönshoff B, Döhler B, Süsal C. Association of graft survival with tacrolimus exposure and late intra-patient tacrolimus variability in pediatric and young adult renal transplant recipients-an international CTS registry analysis. Transpl Int 2020;33:1681-92. [PMID: 32881096 DOI: 10.1111/tri.13726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
73 Skeens MA, Dietrich MS, Ryan-Wenger N, Gilmer MJ, Mulvaney SA, Akard TF. The Medication Level Variability Index (MLVI) as a potential predictive biomarker of graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Pediatr Transplant 2019;23:e13451. [PMID: 31066981 DOI: 10.1111/petr.13451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
74 Prytuła A, van Gelder T. Clinical aspects of tacrolimus use in paediatric renal transplant recipients. Pediatr Nephrol 2019;34:31-43. [DOI: 10.1007/s00467-018-3892-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
75 Harrison JJ, Schiff JR, Coursol CJ, Daley CJ, Dipchand AI, Heywood NM, Keough-Ryan TM, Keown PA, Levy GA, Lien DC, Wichart JR, Cantarovich M. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation 2012;93:657-65. [PMID: 22267158 DOI: 10.1097/TP.0b013e3182445e9d] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
76 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
77 Van Arendonk KJ, King EA, Orandi BJ, James NT, Smith JM, Colombani PM, Magee JC, Segev DL. Loss of pediatric kidney grafts during the "high-risk age window": insights from pediatric liver and simultaneous liver-kidney recipients. Am J Transplant 2015;15:445-52. [PMID: 25612497 DOI: 10.1111/ajt.12985] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
78 Takeda M, Sakamoto S, Irie R, Uchida H, Shimizu S, Yanagi Y, Abdelwahed MS, Fukuda A, Kasahara M. Late T cell-mediated rejection may contribute to poor outcomes in adolescents and young adults with liver transplantation. Pediatr Transplant 2020;24:e13708. [PMID: 32333637 DOI: 10.1111/petr.13708] [Reference Citation Analysis]
79 Cushman GK, Rich KL, Rea KE, Quast LF, Stolz MG, Gutierrez-Colina AM, Eaton CK, Lee JL, Mee LL, George R, Blount RL. Caregivers' Barriers to Facilitating Medication Adherence in Adolescents/Young Adults With Solid Organ Transplants: Measure Development and Validation. J Pediatr Psychol 2020;45:498-508. [PMID: 32374379 DOI: 10.1093/jpepsy/jsaa023] [Reference Citation Analysis]
80 Defrancq C, De Wilde N, Raes A, Van Biervliet S, Vande Velde S, Van Winckel M, De Bruyne R, Prytuła A. Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients: Evolution, risk factors, and impact on patient outcomes. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
81 Gueta I, Markovits N, Yarden-bilavsky H, Raichlin E, Freimark D, Lavee J, Loebstein R, Peled Y. High tacrolimus trough level variability is associated with rejections after heart transplant. Am J Transplant 2018;18:2571-8. [DOI: 10.1111/ajt.15016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
82 Duncan S, Annunziato RA, Dunphy C, LaPointe Rudow D, Shneider BL, Shemesh E. A systematic review of immunosuppressant adherence interventions in transplant recipients: Decoding the streetlight effect. Pediatr Transplant 2018;22. [PMID: 29218760 DOI: 10.1111/petr.13086] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
83 Vondrak K, Parisi F, Dhawan A, Grenda R, Webb NJA, Marks SD, Debray D, Holt RCL, Lachaux A, Kelly D, Kazeem G, Undre N. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus. Clin Transplant 2019;33:e13698. [PMID: 31436896 DOI: 10.1111/ctr.13698] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Hwang YH, Kim H, Min K, Yang J. Tacrolimus trough levels in kidney transplant recipients. BMC Nephrol 2021;22:405. [PMID: 34876046 DOI: 10.1186/s12882-021-02622-5] [Reference Citation Analysis]
85 Eaton CK, Gutierrez-Colina AM, Quast LF, Liverman R, Lee JL, Mee LL, Reed-Knight B, Cushman G, Chiang G, Romero R, Mao C, Garro R, Blount RL. Multimethod Assessment of Medication Nonadherence and Barriers in Adolescents and Young Adults With Solid Organ Transplants. J Pediatr Psychol 2018;43:789-99. [PMID: 29562247 DOI: 10.1093/jpepsy/jsy016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
86 Leino AD, Park JM, Pasternak AL. Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients. Pharmacotherapy 2021;41:649-57. [PMID: 34129685 DOI: 10.1002/phar.2601] [Reference Citation Analysis]
87 Abu Bakar K, Mohamad NA, Hodi Z, McCulloch T, Williams A, Christian M, Key T, Kim JJ. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients. Pediatr Nephrol 2019;34:2557-62. [PMID: 31520127 DOI: 10.1007/s00467-019-04346-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Kaya Aksoy G, Comak E, Koyun M, Akbaş H, Akkaya B, Aydınlı B, Uçar F, Akman S. Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children. Eur J Drug Metab Pharmacokinet 2019;44:539-48. [DOI: 10.1007/s13318-019-00544-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
89 Flahault A, Anglicheau D, Loriot MA, Thervet E, Pallet N. Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes. Pharmacogenomics 2017;18:165-73. [PMID: 27977332 DOI: 10.2217/pgs-2016-0146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
90 Shneider C, Dunphy C, Shemesh E, Annunziato RA. Assessment and Treatment of Nonadherence in Transplant Recipients. Gastroenterol Clin North Am 2018;47:939-48. [PMID: 30337042 DOI: 10.1016/j.gtc.2018.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
91 Shellmer DA, Dabbs AD, Dew MA. Medical adherence in pediatric organ transplantation: what are the next steps? Curr Opin Organ Transplant 2011;16:509-14. [PMID: 21836517 DOI: 10.1097/MOT.0b013e32834a8c89] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
92 Lawrence ZE, Martinez M, Lobritto S, Chen J, Breslin N, Fox A, Vittorio J. Adherence, Medical Outcomes, and Health Care Costs in Adolescents/Young Adults Following Pediatric Liver Transplantation. Journal of Pediatric Gastroenterology & Nutrition 2020;70:183-9. [DOI: 10.1097/mpg.0000000000002553] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
93 Snell GI, Paraskeva MA, Levvey BJ, Westall GP. Immunosuppression for lung transplant recipients. Curr Respir Care Rep 2014;3:88-95. [DOI: 10.1007/s13665-014-0081-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Ryan JL, Dandridge LM, Fischer RT. Adherence to laboratory testing in pediatric liver transplant recipients. Pediatr Transplant 2021;25:e13899. [PMID: 33131187 DOI: 10.1111/petr.13899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, Hesselink DA. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 2017;13:1225-36. [PMID: 29084469 DOI: 10.1080/17425255.2017.1395413] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
96 Sagar N, Leithead JA, Lloyd C, Smith M, Gunson BK, Adams DH, Kelly D, Ferguson JW. Pediatric Liver Transplant Recipients Who Undergo Transfer to the Adult Healthcare Service Have Good Long-Term Outcomes: Pediatric Liver Transplant Patient Transfer. American Journal of Transplantation 2015;15:1864-73. [DOI: 10.1111/ajt.13184] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
97 Mcdiarmid SV. 21 Years Old-Who Cares?: Adults Transplanted as Children. American Journal of Transplantation 2012;12:1367-9. [DOI: 10.1111/j.1600-6143.2012.04085.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Hsiau M, Fernandez HE, Gjertson D, Ettenger RB, Tsai EW. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. Transplantation. 2011;92:918-922. [PMID: 21857278 DOI: 10.1097/tp.0b013e31822dc34f] [Cited by in Crossref: 80] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
99 Pizzo HP, Ettenger RB, Gjertson DW, Reed EF, Zhang J, Gritsch HA, Tsai EW. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence. Pediatr Nephrol 2016;31:2345-52. [PMID: 27286686 DOI: 10.1007/s00467-016-3422-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
100 Goodall DL, Willicombe M, McLean AG, Taube D. High Intrapatient Variability of Tacrolimus Levels and Outpatient Clinic Nonattendance Are Associated With Inferior Outcomes in Renal Transplant Patients. Transplant Direct 2017;3:e192. [PMID: 28795143 DOI: 10.1097/TXD.0000000000000710] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
101 Shuker N, Shuker L, van Rosmalen J, Roodnat JI, Borra LC, Weimar W, Hesselink DA, van Gelder T. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transpl Int 2016;29:1158-67. [PMID: 27188932 DOI: 10.1111/tri.12798] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
102 Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014;85:1404-11. [PMID: 24336032 DOI: 10.1038/ki.2013.465] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 13.7] [Reference Citation Analysis]
103 Arreola-Guerra JM, Alberú J, Chew-Wong A, Macias DM, Hernández-Rosales J, Zuñiga-Macías L, Delgadillo-Castañeda R, Ricalde-Ríos G, Haro-Alcalde F, Villafán-Bernal JR, Ramos-Medellín CL, Reyes-Acevedo R. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients. Clin Transplant 2019;33:e13749. [PMID: 31691354 DOI: 10.1111/ctr.13749] [Reference Citation Analysis]
104 Chu MC, Smith PJ, Reynolds JM, Palmer SM, Snyder LD, Gray AL, Blumenthal JA. Depression, Immunosuppressant Levels, and Clinical Outcomes in Postlung Transplant Recipients. Int J Psychiatry Med 2020;55:421-36. [DOI: 10.1177/0091217420906637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Moiseev IS, Burmina EA, Muslimov AR, Pirogova OV, Bondarenko SN, Darskaya EI, Tarakanova YA, Senina NG, Afanasyev BV. Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis. Ann Hematol 2017;96:935-42. [PMID: 28343273 DOI: 10.1007/s00277-017-2975-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
106 Tanzi MG, Undre N, Keirns J, Fitzsimmons WE, Brown M, First MR. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients. Clin Transplant 2016;30:901-11. [PMID: 27220013 DOI: 10.1111/ctr.12763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
107 Wright J, Elwell L, Mcdonagh JE, Kelly DA, Wray J. Parents in transition: Experiences of parents of young people with a liver transplant transferring to adult services. Pediatr Transplantation 2017;21:e12760. [DOI: 10.1111/petr.12760] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
108 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
109 Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, Woodle ES, Alloway RR, Rohan JM. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant 2019;19:1410-20. [DOI: 10.1111/ajt.15199] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
110 Rook M, Rand E. Predictors of long-term outcome after liver transplant. Curr Opin Organ Transplant 2011;16:499-504. [PMID: 21897246 DOI: 10.1097/MOT.0b013e32834a945d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
111 Riva N, Woillard JB, Distefano M, Moragas M, Dip M, Halac E, Cáceres Guido P, Licciardone N, Mangano A, Bosaleh A, de Davila MT, Schaiquevich P, Imventarza O. Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients. Liver Transpl 2019;25:1397-407. [PMID: 31102573 DOI: 10.1002/lt.25495] [Reference Citation Analysis]
112 Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S. High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplant Direct 2019;5:e424. [PMID: 30882028 DOI: 10.1097/TXD.0000000000000862] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Weiler N, Thrun I, Eberlin M, Foltys D, Heise M, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? Transplant Proc 2013;45:2321-5. [PMID: 23953543 DOI: 10.1016/j.transproceed.2013.03.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
114 Yazigi NA. Long term outcomes after pediatric liver transplantation. Pediatr Gastroenterol Hepatol Nutr. 2013;16:207-218. [PMID: 24511516 DOI: 10.5223/pghn.2013.16.4.207] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
115 Ivulich S, Dooley M, Kirkpatrick C, Snell G. Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post–Lung Transplantation. Transplantation Proceedings 2017;49:2153-60. [DOI: 10.1016/j.transproceed.2017.07.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]